Are peptides safe? What clinical trials and regulators report

The question are peptides safe depends on the specific compound, its regulatory status and the available human evidence.

Basics7 min read

Key takeaway

Some peptide-based medicines have FDA-approved uses and substantial trial evidence. Other compounds remain investigational or have little human safety information. The FDA has identified compounding concerns for certain substances. These include immunogenicity, peptide impurities and inadequate safety data.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited5
Related productsResearch peptide catalog

Are peptides safe is not a question with one answer for the entire category. Peptides include many different molecules, with different purposes, evidence bases and regulatory statuses. Clinical trials and regulator notices show why each compound must be considered separately.

Quick answer: There is no single safety finding that applies to all peptides. Evidence differs by compound, formulation and regulatory status. FDA-approved prescription products have product-specific labels, while many research peptides have no FDA-approved human-use indication and limited clinical evidence.

Are peptides safe across every compound?

Peptides are a broad group of molecules, not one medicine or one therapeutic class. A safety finding for one peptide cannot automatically be applied to another. The evidence also depends on what was studied, which participants were enrolled, how long they were followed and which outcomes researchers measured.

A randomized clinical trial describes adverse events in a defined population. An FDA label summarizes findings, warnings and post-marketing information for a specific approved product. A compounding notice may instead identify evidence gaps or technical concerns. These sources are not equivalent.

Semaglutide and tirzepatide are active ingredients in FDA-approved prescription products. Their labels report gastrointestinal adverse reactions and other warnings. Those findings apply to specific medicines and study populations, not to every peptide (Wegovy label; Zepbound label).

What do clinical trials show for FDA-approved peptide medicines?

Clinical trials of approved peptide-based medicines provide defined safety data, but they do not show an absence of adverse events. In the STEP 1 trial, adults with overweight or obesity received semaglutide or placebo. Nausea was reported in 44.2% of semaglutide participants and 17.4% of placebo participants. Diarrhea, vomiting and constipation were also more frequent in the semaglutide group (Wilding et al., 2021).

In the SURMOUNT-1 trial, adults with obesity or overweight without type 2 diabetes received tirzepatide or placebo. At least one treatment-emergent adverse event was reported in 78.9% to 81.8% of tirzepatide participants and 72.0% of placebo participants. The most frequently reported events were gastrointestinal, including nausea, diarrhea and constipation (Jastreboff et al., 2022).

These figures show why the wording of a safety statement matters. An adverse event is an event reported during a study. It is not automatically proof that the study medicine caused the event. Researchers assess causality separately, and trial reports distinguish adverse events, serious adverse events and treatment discontinuations.

Table 1

What do clinical trials show for FDA-approved peptide medicines

Evidence categoryWhat the sources establishWhat they do not establish
FDA-approved medicine labelProduct-specific trial findings, warnings and approved indicationsThat every product containing a similar molecule has the same quality or regulatory status
Investigational clinical trialFindings for the compound, study population and follow-up periodA complete long-term safety profile or FDA approval
FDA compounding safety noticeIdentified gaps or concerns for nominated substances proposed for compoundingA blanket finding about every peptide, every research material or every seller
Anti-doping prohibited listWhether a substance falls within sport anti-doping rulesA clinical safety assessment or FDA approval decision

What concerns has the FDA identified for certain research compounds?

The FDA maintains a page identifying certain bulk drug substances proposed for compounding that may present significant safety risks. Its list includes several peptides and peptide-related substances. The agency's concerns vary by compound and include limited safety information, potential immunogenicity, aggregation, peptide-related impurities and difficulty characterizing the active ingredient (FDA, Certain Bulk Drug Substances).

For BPC-157, the FDA states that it has identified no or limited safety-related information for the proposed applications. It also identifies potential immunogenicity concerns and complexities involving peptide-related impurities and active pharmaceutical ingredient characterization. The agency says it lacks sufficient information to know whether the substance would cause harm when administered to humans in the proposed settings (FDA, BPC-157 entry).

For CJC-1295, the FDA identifies potential immunogenicity and peptide-impurity concerns. It also states that serious adverse events, including increased heart rate and systemic vasodilatory reaction, have been associated with CJC-1295. The agency describes the available clinical data as limited. This is a compound-specific statement from the FDA's compounding safety review, not a general finding about every peptide (FDA, CJC-1295 entry).

For injectable GHK-Cu, the FDA identifies possible immunogenicity associated with aggregation and peptide-related impurities. It states that limited human data are available to inform safety considerations. For MOTS-c, the agency has not identified human exposure data on drug products containing the substance. It also lacks important information about potential safety issues. It makes a similar limited-information statement for several other nominated peptides (FDA, compounding safety page).

The scope of this FDA page is important. It concerns bulk substances nominated for use in compounding and identified under the agency's interim policies. It does not evaluate every research-material product or every supplier. It is also not an affirmative safety assessment. The agency's stated concerns should be reported substance by substance.

Does research-use-only labeling establish safety?

A research-use-only statement describes the stated purpose of a material. It does not substitute for clinical evidence, FDA review or proof of product quality. It also does not turn an unapproved substance into an FDA-approved medicine.

The FDA has separately warned about unapproved versions of GLP-1 medicines used for weight reduction. It states that such products do not undergo FDA review for safety, effectiveness and quality before marketing. The agency has also reported adverse-event reports involving compounded semaglutide and tirzepatide and noted that these reports may be undercounted (FDA, concerns with unapproved GLP-1 drugs).

A certificate of analysis can document selected tests and results for a particular lot. It does not establish human safety or FDA approval. It also does not show that a particular use has been evaluated in clinical trials. Its value depends on the identity of the tested lot, the methods used, the laboratory report and the scope of the reported tests. Those are documentation questions, not a substitute for clinical evidence.

What does the World Anti-Doping Agency say about peptides?

The World Anti-Doping Agency's 2026 Prohibited List identifies several peptide-related categories that are prohibited in and out of competition. The list includes growth hormone-releasing hormone analogues such as CJC-1295, growth hormone secretagogues such as ipamorelin, and growth hormone-releasing peptides. It also includes thymosin-beta-4 and derivatives such as TB-500 (WADA, 2026 Prohibited List).

The list also places BPC-157 in its S0 category for non-approved substances. WADA defines that category by reference to substances without current approval from a governmental regulatory health authority for human therapeutic use. The definition remains subject to the terms of the list (WADA, 2026 Prohibited List).

WADA's list is an anti-doping standard. It is not an FDA approval list or a clinical safety review. A substance's prohibited status in sport does not, by itself, quantify its medical risks. Conversely, absence from the prohibited list does not establish that a substance is safe or approved.

What can the human evidence show for compounds with limited data?

Human evidence also varies widely. A Phase 2 randomized trial of ipamorelin enrolled 117 adults undergoing bowel resection, with 114 included in the safety population. Treatment-emergent adverse events were reported in 87.5% of the ipamorelin group and 94.8% of placebo participants. The authors described the study as a small proof-of-concept trial with limitations (Beck et al., 2014).

That trial cannot establish safety in every research context. The FDA separately identifies limited safety information and concerns about aggregation and peptide impurities for ipamorelin acetate (FDA, compounding safety page).

Retatrutide illustrates a different evidence stage. Phase 2 and Phase 3 trials have reported safety outcomes, including gastrointestinal adverse events. The compound remains investigational. It had no FDA-approved prescribing label as of November 17, 2026 (Jastreboff et al., 2023; Jastreboff et al., 2026; Lilly, updated October 2026).

Frequently asked questions

Are peptides safe?

There is no single answer for all peptides. FDA-approved medicines have product-specific clinical evidence and warnings. Other compounds remain investigational or have limited human safety information.

Are research peptides FDA approved?

A research-use designation does not mean a compound is FDA approved for human use. Regulatory status must be checked for each specific substance and product.

Does a certificate of analysis prove a peptide is safe?

No. A certificate can document selected tests and results for a particular lot. It does not establish human safety, an approved medical use or FDA approval.

Is BPC-157 FDA approved?

The FDA's compounding safety page identifies limited safety-related information for BPC-157 and describes potential concerns about immunogenicity and peptide impurities. The 2026 WADA list includes BPC-157 under its non-approved substances category.

Are peptides banned in sport?

Some peptide-related substances are prohibited under the 2026 WADA Prohibited List. The exact classification depends on the substance. WADA's list is an anti-doping rule, not a general safety assessment.

What to know now

  • Safety evidence differs by compound. Results for one peptide should not be generalized to the wider category.
  • FDA-approved peptide medicines have product-specific labels, while many research compounds have limited or no human safety information.
  • The FDA and WADA publish different kinds of regulatory information. Neither a research-use statement nor a supplier certificate replaces those sources.

What we’re watching

  • FDA updates to its compounding bulk-substance reviews may change the information available for specific peptide nominations.
  • New human trials and peer-reviewed publications may clarify the evidence for individual compounds. No blanket safety conclusion should be drawn from a new result involving a different peptide.
  • WADA's annual Prohibited List may change the anti-doping status of specific substances in future editions.

Also in the library

Sources: U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; U.S. National Library of Medicine 2026; U.S. National Library of Medicine 2026; World Anti-Doping Agency 2025; Wilding 2021, The New England Journal of Medicine, 384; Jastreboff 2022, The New England Journal of Medicine, 387; Beck 2014, International Journal of Colorectal Disease, 29; National Library of Medicine 2014; Jastreboff 2023, The New England Journal of Medicine, 389; Jastreboff 2026, The New England Journal of Medicine, 395; Eli Lilly and Company 2026. All 12 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  3. U.S. National Library of Medicine. (2026). Wegovy (semaglutide) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. U.S. National Library of Medicine. (2026). Zepbound (tirzepatide) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. World Anti-Doping Agency. (2025). 2026 Prohibited List: International Standard. Effective January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  6. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384, 989–1002. https://doi.org/10.1056/NEJMoa2032183
  7. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387, 205–216. https://doi.org/10.1056/NEJMoa2206038
  8. Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
  9. National Library of Medicine. (2014). Ipamorelin for the management of postoperative ileus (NCT00672074). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00672074
  10. Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. The New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
  11. Jastreboff, A. M., et al. (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity. The New England Journal of Medicine, 395, 1781–1793. https://doi.org/10.1056/NEJMoa2604169
  12. Eli Lilly and Company. (2026). What to know about retatrutide. Updated October 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide